Response2.docx

After noticing the situation which was very  uneven, disclosing the information should not be encouraged by any of the institutions as not only be me because the research is just a trail which was not concluded to launch the drug into the markets .After the publicity about the drug regarding Pergonal and Serophene, if the drug may have the acceptance from the standard health organisations, even though the people who have the problems with cancer might not consume or purchase the drug due o fear about their fertility by expanding their families to be more happier .These factors may affect the well being of the researches by making their reputation to decline by publishing the articles in very illegal way for gaining more benefits because of mobilising several kinds of not  useful information (Islam, 2019).
            The drug is not much dangerous as of advertising by several publications and at the same time FDA commissioner ordered to disclose he information for making the women to know about the drug .But my intention was the trails are just preliminary and not completed as of the date which was published in the articles of American Journal Of Epidemiology is not an ethical issue because it effects highly on the organisation customer retention by making the reputation to drown drastically. Women has the complete rights about the drugs but the drug didn’t get approval .The main thing which is to be noted is that at the times of clinical researches the drug may undertake various factors before accepting it by the major organisations but the research is under at the initial stages .In order to present into the markets, the drug characteristics should be explained clearly so there is no need of giving the details of the drug before because the competitors might take it as  a opportunity to develop better than us (Islam, 2019).